Clinical Trials Logo
  1. Home
  2. Pneumonia, Viral
  3. NCT04322565

Colchicine Counteracting Inflammation in COVID-19 Pneumonia — ColCOVID-19  

Pneumonia, Viral Clinical Trial

Official title:
Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia

Clinical Trial Summary

Cytokines and chemokines are thought to play an important role in immunity and immunopathology during virus infections [3]. Patients with severe COVID-19 have higher serum levels of pro-inflammatory cytokines (TNF-α, IL-1 and IL-6) and chemokines (IL-8) compared to individuals with mild disease or healthy controls, similar to patients with SARS or MERS . The change of laboratory parameters, including elevated serum cytokine, chemokine levels, and increased NLR in infected patients are correlated with the severity of the disease and adverse outcome, suggesting a possible role for hyper-inflammatory responses in COVID-19 pathogenesis. Importantly, previous studies showed that viroporin E, a component of SARS-associated coronavirus (SARS-CoV), forms Ca2C-permeable ion channels and activates the NLRP3 inflammasome. In addition, another viroporin 3a was found to induce NLRP3 inflammasome activation . The mechanisms are unclear. Colchicine, an old drug used in auto-inflammatory disorders (i.e., Familiar Mediterranean Fever and Bechet disease) and in gout, counteracts the assembly of the NLRP3 inflammasome, thereby reducing the release of IL-1b and an array of other interleukins, including IL-6, that are formed in response to danger signals. Recently, colchicine has been successfully used in two cases of life-threatening post-transplant capillary leak syndrome. These patients had required mechanically ventilation for weeks and hemodialysis, before receiving colchicine, which abruptly restored normal respiratory function and diuresis over 48 hrs [4].

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04322565
Study type Interventional
Source Azienda Ospedaliero-Universitaria di Parma
Contact
Status Completed
Phase Phase 2
Start date April 20, 2020
Completion date October 1, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04517123 - Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study N/A
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed NCT01271842 - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study N/A
Completed NCT04724538 - Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19 Phase 1/Phase 2
Recruiting NCT04414293 - Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis N/A
Completed NCT04047719 - Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Recruiting NCT04528888 - Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Phase 3
Completed NCT04606407 - Inhaled NO for the Treatment of Viral Pneumonia in Adults N/A
Terminated NCT04619693 - Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
Recruiting NCT05077917 - Cromolyn Sodium for Treatment of COVID-19 Pneumonia Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT05976581 - Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients N/A
Active, not recruiting NCT04381364 - Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) Phase 2
Completed NCT04422613 - Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia N/A
Completed NCT04479540 - Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease N/A
Recruiting NCT04474340 - COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients Phase 1
Completed NCT04424836 - HFNC Treatment in COVID-19 Pneumonia
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04387799 - Determinants of COVID-19 Pneumonia (MC-19)
Completed NCT04382547 - Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Phase 1/Phase 2